A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults.
Vivaxim is a combined hepatitis A/typhoid fever vaccine (HA/Vi) licensed for vaccination of travellers, but long-term protection against hepatitis A requires two immunisations at least 6 months apart. A randomised, controlled study was performed in 116 healthy adults primed with hepatitis A vaccine (Avaxim) to compare immune responses to HA/Vi and Avaxim given as booster doses 6 months later. Both vaccines elicited marked booster responses achieving antibody geometric mean titres (GMTs) of 4576 and 3760 mIU/ml in the HA/Vi and Avaxim groups, respectively. Although twice as frequent in the HA/Vi group, local reactions (mostly pain) were mainly mild and transient, probably reflecting the larger volume injected (1ml). Vivaxim offers a convenient means of administering both HA and typhoid fever vaccines in subjects already primed for hepatitis A.
Vaccination and Travel Medicine Centre, Poliklinika II, Bratri Stefanu 895, 50003 Hradec Králové, Czech Republic. jiri.beran@vakcinace.cz
Jirí
J
Beran
Roman
R
Chlibek
Françoise
F
Weber
D000293:Adolescent; D000328:Adult; D005260:Female; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D017957:Hepatitis A Virus, Human / Q000276:immunology; D006508:Hepatitis Antibodies / Q000097:blood / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008297:Male; D014436:Typhoid-Paratyphoid Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D017778:Vaccines, Combined; D015164:Vaccines, Inactivated
D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D014436:Typhoid-Paratyphoid Vaccines; D017778:Vaccines, Combined; D015164:Vaccines, Inactivated